Effect of epitope-CpG-DNA-liposome complex without carriers on vaccination of respiratory syncytial virus infection

Journal of the Korean Society for Applied Biological Chemistry

Volumn 57, Issue 5, 2014, Pages 667-676

  Park, Byoung Kwon ^a   Kim, Dongbum ^a   Wu, Guang ^a   Choi, Song Hee ^a   Kim, Doo Sik ^b   Lee, Younghee ^c   Kwon, Hyung Joo ^a  

^a Hallym University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

CpG oligodeoxynucleotide; epitope; respiratory syncytial virus; vaccine

Indexed keywords

EID: 84909578648     PISSN: 17382203     EISSN: 2234344X     Source Type: Journal    
DOI: 10.1007/s13765-014-4215-9     Document Type: Article

References (40)

1. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, and Weiner GJ. (2001) Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol167, 4878–86.
2. Blount RE Jr, Morris JA, and Savage RE. (1956) Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med92, 544–9.
3. Breary SP and Smyth RL. (2007) Pathogenesis of RSV in Children. P.A. Cane (Ed.), Respiratory Syncytial Virus, Perspectives in Medical Virology, vol. 14 Elsevier Publishers, Amsterdam, 141–62.
4. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, Van Uden J, Martin-Orozco E, Gelfand EW, and Raz E. (1998) Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol161, 7054–62.
5. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, and Murphy BR. (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSVimmunized BALB/c mice is abrogated by depletion of interleukin-4 (IL- 4) and IL-10. J Virol68, 5321–5.
6. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC, Sotnikov AV, and Murphy BR. (1992) Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol66, 7444–51.
7. Corvaïa N, Tournier P, Nguyen TN, Haeuw JF, Power UF, Binz H, and Andréoni C. (1997) Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. J Infect Dis176, 560–9.
8. Culley FJ, Pollott J, and Openshaw PJ. (2002) Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med196, 1381–6.
9. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, and Polack FP. (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med15, 34–41.
10. Deng GM, Nilsson IM, Verdrengh M, Collins LV, and Tarkowski A. (1999) Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med5, 702–5.
11. Deshpande SA and Northern V. (2003) The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child88, 1065–9.
12. Eisenberg D, Weiss RM, and Terwilliger TC. (1984) The hydrophobic moment detects periodicity in protein hydrophobicity. Proc Natl Acad Sci USA81, 140–4.
13. Emini EA, Hughes JV, Perlow DS, and Boger J. (1985) Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol55, 836–9.
14. Harris J and Werling D. (2003) Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol5, 671–80.
15. Haynes LM, Jones LP, Barskey A, Anderson LJ, and Tripp RA. (2003) Enhanced disease and pulmonary eosinophilia associated with formalininactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol77, 9831–44.
16. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, and Aguzzi A. (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med10, 187–92.
17. Jameson BA and Wolf H. (1988) The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci4, 181–6.
18. Katz BZ, Lo J, and Sorrentino M. (2003) Costs of Respiratory Syncytial Virus Infection at a Tertiary-Care Children’s Hospital. Pharmacol Ther28, 343–5.
19. Kim D, Kwon HJ, and Lee Y (2011b) Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpGDNA. BMB Rep44, 607–12.
20. Kim D, Kwon S, Ahn CS, Lee Y, Choi SY, Park J, Kwon HY, and Kwon HJ (2011c) Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep44, 758–63.
21. Kim D, Kwon S, Rhee JW, Kim KD, Kim YE, Park CS, Choi MJ, Suh JG, Kim DS, Lee Y, and Kwon HJ (2011a) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol12:29.
22. Kim D, Rhee JW, Kwon S, Sohn WJ, Lee Y, Kim DW, Kim DS, and Kwon HJ. (2009) Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem Biophys Res Commun379, 362–7
23. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, and Parrott RH. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol89, 422–34.
24. Kim S, Jang JE, Yu JR, and Chang J. (2010) Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine28, 3801–8.
25. Klinman DM, Currie D, Gursel I, and Verthelyi D. (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev199, 201–16.
26. Kong X, San Juan H, Kumar M, Behera AK, Mohapatra A, Hellermann GR, Mane S, Lockey RF, and Mohapatra SS. (2003) Respiratory syncytial virus infection activates STAT signaling in human epithelial cells. Biochem Biophys Res Commun306, 616–22.
27. Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim YE, Park CS, Ahn HJ, Seo JN, Choi KC, Kim DS, Lee Y, and Kwon HJ. (2012) Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One7, e33121.
28. Kwon S, Kim D, Park BK, Wu G, Park MC, Ha YW, Kwon HJ, and Lee Y. (2013) Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol Rep29, 735–40.
29. Kyte J and Doolittle RF. (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol157, 105–32.
30. Lee KW, Jung J, Lee Y, Kim TY, Choi SY, Park J, Kim DS, and Kwon HJ. (2006) Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol43, 2107–18.
31. Melero JA. (2007) In Respiratory syncytial virus, Cane PA (ed.), Perspectives in Medical Virology 14, 1–42, Elsevier Publishers, Netherlands.
32. Nallet S, Amacker M, Westerfeld N, Baldi L, König I, Hacker DL, Zaborosch C, Zurbriggen R, and Wurm FM. (2009) Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells. Vaccine27, 6415–9
33. Resch B, Gusenleitner W, and Müller W. (2002) The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection30, 193–7.
34. Rhee JW, Kim D, Park BK, Kwon S, Cho S, Lee I, Park MS, Seo JN, Kim YS, Choi HS, Lee Y, and Kwon HJ. (2012) Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNAliposome complex induced protection against lethal influenza virus infection in mice. PLoS One 7, e48750.
35. Simoes EA. (2003) Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr143(5 Suppl), S118–26.
36. Sparwasser T, Hultner L, Koch ES, Luz A, Lipford GB, and Wagner H. (1999) Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol162, 2368–74.
37. Walsh EE and Falsey AR. (2012) Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets12, 98–102.
38. Wertz GW, Stott EJ, Young KK, Anderson K, and Ball LA. (1987) Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol61, 293–301.
39. Xie C, He JS, Zhang M, Xue SL, Wu Q, Ding XD, Song W, Yuan Y, Li DL, Zheng XX, Lu YY, and Shang Z. (2007) Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther18, 746–52.
40. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, and Heeg K. (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol160, 3627–30.